FDA Awards Priority Voucher for Copper Drug Treating Kids' Disease
Published Date: 2/27/2026
Notice
Summary
The FDA just gave Sentynl Therapeutics a special priority review voucher for their new rare pediatric disease drug, ZYCUBO, which treats Menkes disease in kids. This voucher speeds up future FDA reviews, helping get important medicines to patients faster. The approval happened on January 12, 2026, and this voucher could also be sold or used to speed up other drug reviews, potentially saving time and money.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
ZYCUBO Approved for Menkes Disease
If you have a child with Menkes disease, the FDA approved ZYCUBO (copper histidinate) for treatment on January 12, 2026. This approval means pediatric patients with Menkes disease have an FDA‑approved treatment option.
Priority Review Voucher Can Speed Reviews
The FDA issued a Rare Pediatric Disease Priority Review Voucher tied to ZYCUBO; the voucher can be used or sold to speed the FDA review of another drug. If you or someone you care for needs a rare‑disease medicine, using or selling this voucher can help get other important drugs to patients faster and may save time and money.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16714, Agency Information Collection Activities; Proposed Collection; Comment Request; Third Party Disclosure and Recordkeeping Requirements for Reportable Food
The Food and Drug Administration (FDA or the Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection provisions of FDA's third-party disclosure and recordkeeping requirements for reportable food.
2026-16712, Agency Information Collection Activities; Proposed Collection; Comment Request; Imports and Electronic Import Entries
The FDA wants your thoughts on how they collect info about imports and electronic import entries. If you’re involved in importing goods, this could affect you! They’re asking for comments by October 16, 2026, to help improve the process without adding extra costs or hassle.
2026-16715, Agency Information Collection Activities; Proposed Collection; Comment Request; Investigational New Drug Application Requirements
The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
Previous / Next Documents
Previous: 2026-03924, Certain Beverage Brewing Products and Components Thereof; Notice of Institution of Investigation
Adrian Rivera Maynez Enterprises is asking the U.S. International Trade Commission to investigate certain beverage brewing products that might be breaking their patents. If the investigation agrees, some products could be blocked from being sold or imported into the U.S., which could shake up the market soon. This means companies selling these products should watch out for possible legal changes and restrictions starting in 2026.
Next: 2026-03926, Commercial Driver's License Standards: Application for Exemption Renewal; Wilson Logistics
Wilson Logistics got the green light to keep their special exemption that lets a learner driver train without a fully licensed driver sitting right next to them—once the learner has passed their skills test. This renewal runs from February 24, 2026, to February 24, 2031, and keeps safety standards strong while giving Wilson Logistics some training flexibility. Drivers, trainers, and the company all benefit from this smart, safety-approved update with no extra costs.